Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Total Liabilities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Total Liabilities data on record, last reported at $5.7 million in Q1 2026.

  • On a quarterly basis, Total Liabilities fell 33.2% to $5.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.7 million, a 33.2% decrease, with the full-year FY2025 number at $8.3 million, up 122.33% from a year prior.
  • Total Liabilities reached $5.7 million in Q1 2026 per IKT's latest filing, down from $8.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for IKT hit a ceiling of $8.8 million in Q2 2025 and a floor of $2.8 million in Q1 2023.
  • A 5-year average of $4.9 million and a median of $4.3 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 35.79% in 2023, then soared 135.9% in 2025.
  • Tracing IKT's Total Liabilities over 5 years: stood at $3.9 million in 2022, then fell by 9.54% to $3.5 million in 2023, then increased by 5.8% to $3.7 million in 2024, then soared by 122.33% to $8.3 million in 2025, then tumbled by 31.19% to $5.7 million in 2026.
  • Business Quant data shows Total Liabilities for IKT at $5.7 million in Q1 2026, $8.3 million in Q4 2025, and $6.7 million in Q3 2025.